Search Results 1121-1130 of 21213 for Informed consent

1. Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis - Mayo Clinic

   Must provide written informed consent and agree to comply with the study protocol. ... Mental instability or incompetence, such that the validity of informed ...

2. Specialty Compared to Oncology Delivered Palliative Care for Treating Acute Myeloid Leukemia - Mayo Clinic

   Patients with psychiatric or cognitive conditions which the treating clinicians believe prohibits informed consent or compliance with study procedures.

3. A Master Protocol To Evaluate The Long-Term Safety Of (LY3527727) Pirtobrutinib - Mayo Clinic

   Are participating in an eligible Lilly-sponsored clinical study evaluating pirtobrutinib. Are capable of giving signed informed consent. Exclusion Criteria:.

4. A Study To Evaluate Intralesional Injection Of Triamcinolone Acetonide To Treat Desmoid Tumors - Mayo Clinic

   Willing to sign an informed consent form. Willing to comply with protocol procedures including required 21 month follow up after last injection. Exclusion ...

5. Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma - Mayo Clinic

   Provide written informed consent to participate on the study; Patients must have a pathologically confirmed diagnosis either at MSKCC or at the participating ...

6. Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women - Mayo Clinic

   - Unable or unwilling to give informed consent - Pregnant - Body weight >150 kg or body mass index (BMI) > 50 - QTc>450 msec - Total bilirubin >2X upper ...

7. A Study to Compare A-CP HA Kit, Hyaluronic Acid and Placebo To Treatment Knee Osteoarthritis - Mayo Clinic

   Refusal to sign or inability to give Informed Consent. Inability to understand or comply with the requirements of the study. Any other reason which may ...

8. Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma - Mayo Clinic

   ... informed consent through 90 days after the last dose of study drug, or; agree ... consent may be withdrawn by the participant at any time without ...

9. BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma - Mayo Clinic

   Written informed consent and HIPAA authorization for release of personal health information. ... consent is signed until 4 weeks after treatment discontinuation.

10. Discussions in Shared Decision Making in Accupunture Treatment - Mayo Clinic

    Inability to provide informed consent or HIPAA authorization. Individuals that decline study participation. Patients under the age of 18 years old ...